Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHOS: Risk-stratified reduced-intensity adjuvant treatment after transoral surgery for HPV-positive oropharyngeal cancer
2024-516673-68-00Phase 3Authorised
- Sponsor
- Cardiff University
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised trial of cisplatin and carboplatin in oropharyngeal squamous cell carcinoma (2 arms), sponsored by Cardiff University. Primary endpoints: Overall survival and Swallowing function (MD Anderson Dysphagia Inventory score). Planned start Jan 2025; status: authorised.
02
Drugs
cisplatincarboplatin
03
Conditions
oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on 2024-516673-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516673-68-00.